The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer

Amanda F Baker, Tomislav Dragovich

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The lack of development of new, more effective, therapies for pancreatic cancer has been disappointing. Among the factors limiting the development of targeted therapy approaches has been the inherent molecular heterogeneity of this disease combined with the challenge of obtaining fresh tumor tissue for the identification of pharmacodynamic biomarkers to segment patients based on target expression and resistance factors. Although many pre-clinical studies include pharmacodynamic studies, few large clinical studies have included similar biological correlative endpoints. Gemcitabine, although only modestly effective, still remains the standard of care. Emerging studies have identified potential molecular and genetic markers for cellular transporters and metabolism of gemcitabine which may be useful in predicting both clinical benefit and toxicity from this agent. The continued development of new therapeutics combined with identification of pharmacodynamic biomarkers to predict and monitor response to anti-cancer agents represents an exciting opportunity to individualize therapy and improve outcomes in this challenging disease.

Original languageEnglish (US)
Title of host publicationDrug Discovery in Pancreatic Cancer: Models and Techniques
PublisherSpringer New York
Pages271-289
Number of pages19
ISBN (Print)9781441911599
DOIs
StatePublished - 2010

Fingerprint

gemcitabine
Pancreatic Neoplasms
Biomarkers
R Factors
Therapeutics
Standard of Care
Genetic Markers
Molecular Biology
Neoplasms
Clinical Studies

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Baker, A. F., & Dragovich, T. (2010). The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer. In Drug Discovery in Pancreatic Cancer: Models and Techniques (pp. 271-289). Springer New York. https://doi.org/10.1007/978-1-4419-1160-5_14

The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer. / Baker, Amanda F; Dragovich, Tomislav.

Drug Discovery in Pancreatic Cancer: Models and Techniques. Springer New York, 2010. p. 271-289.

Research output: Chapter in Book/Report/Conference proceedingChapter

Baker, AF & Dragovich, T 2010, The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer. in Drug Discovery in Pancreatic Cancer: Models and Techniques. Springer New York, pp. 271-289. https://doi.org/10.1007/978-1-4419-1160-5_14
Baker AF, Dragovich T. The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer. In Drug Discovery in Pancreatic Cancer: Models and Techniques. Springer New York. 2010. p. 271-289 https://doi.org/10.1007/978-1-4419-1160-5_14
Baker, Amanda F ; Dragovich, Tomislav. / The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer. Drug Discovery in Pancreatic Cancer: Models and Techniques. Springer New York, 2010. pp. 271-289
@inbook{1f79bd679a45469dbb8deeb4dbd2a4e8,
title = "The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer",
abstract = "The lack of development of new, more effective, therapies for pancreatic cancer has been disappointing. Among the factors limiting the development of targeted therapy approaches has been the inherent molecular heterogeneity of this disease combined with the challenge of obtaining fresh tumor tissue for the identification of pharmacodynamic biomarkers to segment patients based on target expression and resistance factors. Although many pre-clinical studies include pharmacodynamic studies, few large clinical studies have included similar biological correlative endpoints. Gemcitabine, although only modestly effective, still remains the standard of care. Emerging studies have identified potential molecular and genetic markers for cellular transporters and metabolism of gemcitabine which may be useful in predicting both clinical benefit and toxicity from this agent. The continued development of new therapeutics combined with identification of pharmacodynamic biomarkers to predict and monitor response to anti-cancer agents represents an exciting opportunity to individualize therapy and improve outcomes in this challenging disease.",
author = "Baker, {Amanda F} and Tomislav Dragovich",
year = "2010",
doi = "10.1007/978-1-4419-1160-5_14",
language = "English (US)",
isbn = "9781441911599",
pages = "271--289",
booktitle = "Drug Discovery in Pancreatic Cancer: Models and Techniques",
publisher = "Springer New York",

}

TY - CHAP

T1 - The development of pharmacodynamic endpoint models for evaluation of therapeutics in pancreatic cancer

AU - Baker, Amanda F

AU - Dragovich, Tomislav

PY - 2010

Y1 - 2010

N2 - The lack of development of new, more effective, therapies for pancreatic cancer has been disappointing. Among the factors limiting the development of targeted therapy approaches has been the inherent molecular heterogeneity of this disease combined with the challenge of obtaining fresh tumor tissue for the identification of pharmacodynamic biomarkers to segment patients based on target expression and resistance factors. Although many pre-clinical studies include pharmacodynamic studies, few large clinical studies have included similar biological correlative endpoints. Gemcitabine, although only modestly effective, still remains the standard of care. Emerging studies have identified potential molecular and genetic markers for cellular transporters and metabolism of gemcitabine which may be useful in predicting both clinical benefit and toxicity from this agent. The continued development of new therapeutics combined with identification of pharmacodynamic biomarkers to predict and monitor response to anti-cancer agents represents an exciting opportunity to individualize therapy and improve outcomes in this challenging disease.

AB - The lack of development of new, more effective, therapies for pancreatic cancer has been disappointing. Among the factors limiting the development of targeted therapy approaches has been the inherent molecular heterogeneity of this disease combined with the challenge of obtaining fresh tumor tissue for the identification of pharmacodynamic biomarkers to segment patients based on target expression and resistance factors. Although many pre-clinical studies include pharmacodynamic studies, few large clinical studies have included similar biological correlative endpoints. Gemcitabine, although only modestly effective, still remains the standard of care. Emerging studies have identified potential molecular and genetic markers for cellular transporters and metabolism of gemcitabine which may be useful in predicting both clinical benefit and toxicity from this agent. The continued development of new therapeutics combined with identification of pharmacodynamic biomarkers to predict and monitor response to anti-cancer agents represents an exciting opportunity to individualize therapy and improve outcomes in this challenging disease.

UR - http://www.scopus.com/inward/record.url?scp=84900247660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900247660&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-1160-5_14

DO - 10.1007/978-1-4419-1160-5_14

M3 - Chapter

SN - 9781441911599

SP - 271

EP - 289

BT - Drug Discovery in Pancreatic Cancer: Models and Techniques

PB - Springer New York

ER -